Cerebral Spinal Fluid Management Market size is anticipated to gain remarkable momentum between 2022 and 2028. This is due to the increasing use of cerebrospinal fluid (CSF) analysis or tests to diagnose meningitis and other infectious diseases of the spinal cord and brain. The strong prevalence of chronic rhinosinusitis with nasal polyps in countries including the United States will also stimulate the need for cerebrospinal fluid leak management devices in the coming years. CSF refers to a clear, colorless liquid that protects the brain and spinal cord by acting like a cushion against injury or sudden impact. This liquid can remove waste products from the brain to ensure the proper functioning of the central nervous system. Varied CSF management devices are used to manage the raised intracranial pressure through the safe elimination of cerebrospinal fluid from ventricles of the lumbar spine or brain.
Rising burden of congenital hydrocephalus among infants will foster market trends during the forecast period. This condition occurs in one or two of every 1,000 infants born in the U.S., according to Johns Hopkins Medicine’s data, which could drive the popularity of cerebrospinal fluid physiology worldwide. Likewise, the potential increase in the incidence rate of brain tumors in the UK will generate further growth opportunities for the overall industry in the coming years, as the growth of brain tumors is associated with CSF leaks through the brain covering.
Considering patient type, the geriatric segment is set to account for a considerable share in the CSF management market by 2028. Growth from the segment is a result of the higher risk of antinuclear antibodies among older people, which is commonly related to autoimmune disorders. As the CSF tests for these disorders are used to identify the levels of protein in cerebrospinal fluid, the disease prevalence could impel product demand among the elderly population. Additionally, the emergence of malignant gliomas as a common primary brain tumor in geriatric people will further augment the deployment of cerebrospinal fluid management systems in the coming years.
The Asia Pacific CSF management market will register a high revenue by 2028, attributed to the robust presence of neurosurgeons in developed economies and the rapid expansion of elderly population. According to the WHO, the population of people aged 60 years or above is expected to reach 28% by 2040 in China. These aforesaid factors, along with the strong prevalence of Japanese encephalitis in the country, will contribute to regional growth during the forecast timeframe.
The competitive landscape of the market comprises companies such as Spiegelberg, Sophysa, Medtronic, Integra LifeSciences, Dispomedica, DePuy Synthes Companies (Johnson & Johnson), BeckerSmith Medical, and B. Braun Melsungen. These companies are focusing on new service launches, business expansions, acquisitions, and mergers to strengthen their footprint across the competitive market.
In the wake of the coronavirus pandemic, healthcare systems worldwide have witnessed severe disruptions owing to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments. The crisis and its resultant impacts have also led to a decline in cancer care or a delay in tumor surgery worldwide. Such factors may have asserted a negative influence on the industry over the past months. However, the industry may regain traction over the forthcoming years, given the emerging cases of CSF leaks among people who have undergone nasal swab testing for coronavirus, owing to injury at the base of the skull.
Market, By Product
Market, By Patient Type
Market, By End-use
The above information is provided for the following regions and countries: